By the end of 2024 TAVR studies
By the end of 2024 TAVR studies:
1-Years of Progress Have Made TAVR More Effective When Treating Concomitant Mitral Stenosis by the End of 2024
A recent study published in Circulation: Cardiovascular Interventions highlights significant advancements in transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis (AS) and severe mitral stenosis (MS). Using modern balloon-expandable valves, such as the SAPIEN 3 Ultra Resilia, TAVR has become safer and more effective for high-risk patients, overcoming previous challenges in treating both conditions simultaneously.
The study analyzed data from over 200,000 TAVR patients (2015–2022) from the TVT Registry.
2- Off-Label TAVR for Native Aortic Regurgitation Linked to Worse Outcomes
A meta-analysis published in JACC: Cardiovascular Interventions shows that using off-label TAVR devices designed for aortic stenosis (AS) to treat pure native aortic regurgitation (AR) results in significantly worse outcomes compared to using devices specifically designed for AR.
Key Findings:
1. Higher Mortality Rates:
• 30-day mortality: 9% with off-label devices vs. 3% with dedicated AR devices.
• One-year mortality: 24% with off-label devices vs. 6% with AR-specific devices.
2. Device Performance:
• Dedicated AR devices (e.g., JenaValve Trilogy, J-Valve) had higher success rates (93% vs. 82%) and lower risks of reintervention, valve embolization, and moderate/severe residual AR.
• Fewer complications with dedicated devices:
• Pacemaker implantation: 11% vs. 20%.
• Major bleeding: 3% vs. 7%.
3. Comparing JenaValve and J-Valve:
• JenaValve was associated with a lower pacemaker rate (6% vs. 21%) and better residual AR outcomes compared to J-Valve.
Conclusion:
Dedicated TAVR devices for AR, such as JenaValve and J-Valve, address anatomical challenges like aortic root dilation and lack of calcification more effectively than off-label AS devices. The study strongly supports prioritizing AR-specific valves for this high-risk population to improve outcomes and reduce complications.
